Salud
Missouri Attorney General warns Eli Lilly over 340B drug discount data requirements
Este resumen todavía no está traducido, así que se muestra en inglés. Leer el original en inglés
Por qué importa
This action highlights an escalating trend of state attorneys general intervening in federal drug pricing disputes and holding pharmaceutical companies accountable.
El resumen
Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter on October 26, directing Eli Lilly to halt its policy requiring hospitals to supply claims data before receiving discounted medications through the federal 340B Drug Pricing Program, STAT reported.[1][2] Hanaway asserted that the pharmaceutical manufacturer breached its commitments by withholding discounts from institutions like University of Missouri Health Care even after data was provided, thereby violating state laws against misleading statements.[3] The warning underscores growing state-level pushback against drugmaker restrictions within public health pricing initiatives. STAT reported that the attorney general gave the company until November 26 to terminate the disputed policy.[4] It remains unconfirmed whether Eli Lilly will comply with the demand or pursue legal challenges against the state directive, according to the reporting.
Respuestas rápidas
- ¿Qué pasó?
- Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter on October 26, directing Eli Lilly to halt its policy requiring hospitals to supply claims data before receiving discounted medications through the federal 340B Drug Pricing Program, STAT reported. Hanaway asserted that the pharmaceutical manufacturer breached its commitments by withholding discounts from institutions like University of Missouri Health Care even after data was provided, thereby violating state laws against misleading statements. The warning underscores growing state-level pushback against drugmaker restrictions within public health pricing initiatives. STAT reported that the attorney general gave the company until November 26 to terminate the disputed policy. It remains unconfirmed whether Eli Lilly will comply with the demand or pursue legal challenges against the state directive, according to the reporting.
- ¿Por qué importa?
- This action highlights an escalating trend of state attorneys general intervening in federal drug pricing disputes and holding pharmaceutical companies accountable.
- ¿Cómo se verificó «Missouri Attorney General warns Eli Lilly over 340B drug discount data requirements»?
- Citelink basó este resumen en 1 fuente, entre ellas STAT News. Las afirmaciones van numeradas y con su estado de evidencia más abajo; las fuentes aparecen en una lista aparte.
Verificación: cada afirmación extraída del resumen, contrastada con las fuentes
Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly on October 26.
The cease-and-desist letter directed Eli Lilly to halt its policy requiring hospitals to supply claims data before receiving discounted medications through the 340B Drug Pricing Program.
Hanaway asserted that Eli Lilly withheld discounts from institutions like University of Missouri Health Care even after data was provided.
The attorney general gave the company until November 26 to terminate the disputed policy.
Comprueba una afirmación tú mismo
Opcional: verifica cualquier afirmación de este resumen con la herramienta de verificación de Citelink (en inglés).
Fuentes
Cómo se hizo este resumen
El sistema automatizado de Citelink redactó este resumen en inglés a partir de la fuente indicadas arriba y verificó con ellas cada afirmación extraída del resumen antes de publicarlo. Después se tradujo automáticamente al español. Ninguna persona revisa cada resumen antes de su publicación, así que consulta las notas originales para conocer la historia completa.
¿Encontraste un error? Solicitar una corrección · Política de correcciones